<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02390466</url>
  </required_header>
  <id_info>
    <org_study_id>IVVAC-3S/P2</org_study_id>
    <nct_id>NCT02390466</nct_id>
  </id_info>
  <brief_title>Open-label, Phase I/IIa Study of VAC-3S in HIV-1 Patients Who Showed an Immune Response to VAC-3S During IVVAC-3S/P1</brief_title>
  <official_title>Multicentre, Open-label, Phase I/IIa Clinical Study of an Immunoprotective Therapeutic Vaccine Candidate (VAC-3S) in Human Immunodeficiency Virus Type 1 (HIV-1) Chronically Infected Patients Virologically Controlled on Antiretroviral Therapy (ART) Who Rose an Immune Response to VAC-3S During IVVAC-3S/P1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InnaVirVax</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InnaVirVax</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of VAC-3S in controlled
      HIV patients receiving standard of care antiretroviral treatment.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients who tolerated 3 vaccinations with VAC-3S 16µg/mL at 4-weeks interval determined by safety parameter changes according to the DAIDS (Division of Acquired Immunodeficiency Syndrome) Adverse Events (AE) Grading Table.</measure>
    <time_frame>From Day 0 to week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients who tolerated a fourth booster injection of VAC-3S 16µg/mL determined by safety parameter changes according to the DAIDS (Division of Acquired Immunodeficiency Syndrome) Adverse Events (AE) Grading Table.</measure>
    <time_frame>From Week 16 to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-3S antibody titers</measure>
    <time_frame>From Day 0 to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of progression to AIDS. Markers include CD4+ cell count, viral load, and phenotypic markers of lymphocyte differentiation and activation</measure>
    <time_frame>From Day 0 to Week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>VAC-3S</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>32µg/ml corresponding to 16µg/vaccination</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VAC-3S</intervention_name>
    <description>Administered via intra-muscular injection in the arm</description>
    <arm_group_label>VAC-3S</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infected patient,

          -  Age between 18 and 60 years,

          -  ART (Anti Retroviral Therapy) initiation ≥ 1 year ago,

          -  Plasma HIV RNA ≤ 200 copies/ml in the past 12 months,

          -  Plasma HIV RNA ≤ 50 copies/ml at the screening visit,

          -  CD4+ T cell count ≥ 200 cells/mm3,

          -  Nadir CD4+ T cell count ≥ 100 cells/mm3,

          -  Contraception in women with child-bearing potential,

          -  A total anti-3S titer ≥ 20 A.U. at any time point of IVVAC-3S/P1 clinical trial,

          -  Per protocol subject having completed the IVVAC-3S/P1 study.

          -  Patient affiliated to a social security system,

          -  Patient who has understood the protocol design and provided a signed written informed
             consent form,

          -  Patient who is willing and capable of cooperating to the extent and degree required by
             the protocol,

          -  Patient whom the investigator believes he/she can and will comply with the
             requirements of the protocol (e.g. completion of the diary cards, return for follow-up
             visits) and he/she will be available for all scheduled visits at the investigational
             site.

        Exclusion Criteria:

          -  Administration of VAC-3S in the past year,

          -  Chronic active liver disease,

          -  History of HCV co-infection or ongoing replicating HCV (positive RT-PCR) or HBV
             (positive HbS Ag) coinfection,

          -  Any immunotherapy (e.g. IL-2, IL-7, growth hormone…) in the past year at the exception
             of VAC-3S,

          -  Any immunosuppressive therapy (glucocorticoids, cyclosporine, methotrexate) or chronic
             non-steroidal anti-inflammatory treatment in the past month,

          -  Ongoing pregnancy,

          -  Breastfeeding women,

          -  Patient with known sensitivities to investigational drug (see please the CIB),

          -  History of allergy to any vaccine,

          -  Any severe chronic condition that would interfere with the study,

          -  History of auto-immune disease,

          -  Organ transplant,

          -  Splenectomy,

          -  Psychiatric disorder significant enough to hinder participation as assessed by the
             investigator,

          -  Patient who has participated in a clinical research trial in the 30 days preceding the
             screening visit (V-1M-1).

          -  Patients with contraindications to intramuscular injections including, but not limited
             to, patients with thrombocytopenia and/or anomalies of the coagulation system,

          -  Any uncontrolled chronic or acute condition that in the opinion of the investigator
             would compromise the safety of the patient or the ability to properly administer the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raphaël Ho Tsong Fang, DVM PhD</last_name>
    <role>Study Director</role>
    <affiliation>InnaVirVax</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin Saint Vincent de Paul</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2015</study_first_submitted>
  <study_first_submitted_qc>March 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2015</study_first_posted>
  <last_update_submitted>June 16, 2016</last_update_submitted>
  <last_update_submitted_qc>June 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

